[Hypereosinophilic syndrome and Löffler endocarditis caused by FIP1L-PDGFRA rearrangement: effectiveness of imatinib mesylate therapy]

Med Clin (Barc). 2007 Jun 23;129(4):159. doi: 10.1157/13107495.
[Article in Spanish]
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Benzamides
  • Humans
  • Hypereosinophilic Syndrome / drug therapy*
  • Hypereosinophilic Syndrome / etiology*
  • Imatinib Mesylate
  • Male
  • Middle Aged
  • Oncogene Proteins, Fusion*
  • Piperazines / therapeutic use*
  • Protein Kinase Inhibitors / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Receptor, Platelet-Derived Growth Factor alpha*
  • mRNA Cleavage and Polyadenylation Factors*

Substances

  • Benzamides
  • Oncogene Proteins, Fusion
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • mRNA Cleavage and Polyadenylation Factors
  • Imatinib Mesylate
  • FIP1L1-PDGFRA fusion protein, human
  • Receptor, Platelet-Derived Growth Factor alpha